ALPRE Fundamental Analysis - PREDILIFE SA

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to ALPRE. ALPRE was compared to 83 industry peers in the Biotechnology industry. ALPRE may be in some trouble as it scores bad on both profitability and health. ALPRE is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

ALPRE had negative earnings in the past year.

In the past year ALPRE has reported a negative cash flow from operations.

ALPRE had negative earnings in each of the past 5 years.

In the past 5 years ALPRE always reported negative operating cash flow.

1.2 Ratios

ALPRE has a Return On Assets of -290.42%. This is amonst the worse of the industry: ALPRE underperforms 95.18% of its industry peers.

		Industry Rank	Sector Rank
ROA	-290.42%
ROE	N/A
ROIC	N/A

ROA(3y)-115.89%

ROA(5y)-97.74%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 98.10%, ALPRE belongs to the top of the industry, outperforming 96.39% of the companies in the same industry.

ALPRE's Gross Margin has improved in the last couple of years.

The Profit Margin and Operating Margin are not available for ALPRE so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	98.1%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y14.18%

GM growth 5Y8.21%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALPRE does not have a ROIC to compare to the WACC, probably because it is not profitable.

ALPRE has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, ALPRE has more shares outstanding

The debt/assets ratio for ALPRE is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -38.89, we must say that ALPRE is in the distress zone and has some risk of bankruptcy.

ALPRE's Altman-Z score of -38.89 is on the low side compared to the rest of the industry. ALPRE is outperformed by 85.54% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-38.89

ROIC/WACCN/A

WACC6.67%

2.3 Liquidity

A Current Ratio of 0.45 indicates that ALPRE may have some problems paying its short term obligations.

With a Current ratio value of 0.45, ALPRE is not doing good in the industry: 89.16% of the companies in the same industry are doing better.

A Quick Ratio of 0.45 indicates that ALPRE may have some problems paying its short term obligations.

ALPRE's Quick ratio of 0.45 is on the low side compared to the rest of the industry. ALPRE is outperformed by 87.95% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.45
Quick Ratio	0.45

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 20.59% over the past year.

The Revenue has grown by 134.19% in the past year. This is a very strong growth!

ALPRE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 84.77% yearly.

EPS 1Y (TTM)20.59%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%21.88%

Revenue 1Y (TTM)134.19%

Revenue growth 3Y51.41%

Revenue growth 5Y84.77%

Sales Q2Q%148.77%

3.2 Future

The Earnings Per Share is expected to decrease by -12.92% on average over the next years. This is quite bad

Based on estimates for the next years, ALPRE will show a very strong growth in Revenue. The Revenue will grow by 116.42% on average per year.

EPS Next Y-10.83%

EPS Next 2Y-12.92%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year50.7%

Revenue Next 2Y51.3%

Revenue Next 3Y161.34%

Revenue Next 5Y116.42%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALPRE. In the last year negative earnings were reported.

Also next year ALPRE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ALPRE's earnings are expected to decrease with -12.92% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-12.92%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ALPRE does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PREDILIFE SA

EPA:ALPRE (12/5/2025, 7:00:00 PM)

3.38

+0.04 (+1.2%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst OwnersN/A

Inst Owner ChangeN/A

Ins Owners49.01%

Ins Owner ChangeN/A

Market Cap12.81M

Revenue(TTM)728.10K

Net Income(TTM)-3.80M

Analysts86.67

Price Target21.34 (531.36%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	17.59
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-0.99

EYN/A

EPS(NY)-1.58

Fwd EYN/A

FCF(TTM)-0.74

FCFYN/A

OCF(TTM)-0.73

OCFYN/A

SpS0.19

BVpS-1.53

TBVpS-1.54

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-290.42%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	98.1%
FCFM	N/A

ROA(3y)-115.89%

ROA(5y)-97.74%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y14.18%

GM growth 5Y8.21%

F-Score2

Asset Turnover0.56

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	0.89%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.45
Quick Ratio	0.45
Altman-Z	-38.89

F-Score2

WACC6.67%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)7.93%

Cap/Sales(5y)11.32%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)20.59%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%21.88%

EPS Next Y-10.83%

EPS Next 2Y-12.92%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)134.19%

Revenue growth 3Y51.41%

Revenue growth 5Y84.77%

Sales Q2Q%148.77%

Revenue Next Year50.7%

Revenue Next 2Y51.3%

Revenue Next 3Y161.34%

Revenue Next 5Y116.42%

EBIT growth 1Y17.44%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year16.48%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y12.75%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y12.01%

OCF growth 3YN/A

OCF growth 5YN/A

PREDILIFE SA / ALPRE.PA FAQ

Can you provide the ChartMill fundamental rating for PREDILIFE SA?

ChartMill assigns a fundamental rating of 2 / 10 to ALPRE.PA.

What is the valuation status of PREDILIFE SA (ALPRE.PA) stock?

ChartMill assigns a valuation rating of 0 / 10 to PREDILIFE SA (ALPRE.PA). This can be considered as Overvalued.

How profitable is PREDILIFE SA (ALPRE.PA) stock?

PREDILIFE SA (ALPRE.PA) has a profitability rating of 1 / 10.

What is the expected EPS growth for PREDILIFE SA (ALPRE.PA) stock?

The Earnings per Share (EPS) of PREDILIFE SA (ALPRE.PA) is expected to decline by -10.83% in the next year.

PREDILIFE SA (ALPRE.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

PREDILIFE SA / ALPRE.PA FAQ

Can you provide the ChartMill fundamental rating for PREDILIFE SA?

What is the valuation status of PREDILIFE SA (ALPRE.PA) stock?

How profitable is PREDILIFE SA (ALPRE.PA) stock?

What is the expected EPS growth for PREDILIFE SA (ALPRE.PA) stock?